Eton Pharmaceuticals (NASDAQ:ETON) Insider David Krempa Sells 42,797 Shares

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) insider David Krempa sold 42,797 shares of the business’s stock in a transaction that occurred on Friday, May 22nd. The shares were sold at an average price of $33.39, for a total transaction of $1,428,991.83. Following the completion of the transaction, the insider owned 25,249 shares of the company’s stock, valued at $843,064.11. The trade was a 62.89% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

David Krempa also recently made the following trade(s):

• On Tuesday, May 26th, David Krempa sold 37,524 shares of Eton Pharmaceuticals stock. The shares were sold at an average price of $31.49, for a total transaction of $1,181,630.76.
• On Wednesday, May 27th, David Krempa sold 19,679 shares of Eton Pharmaceuticals stock. The shares were sold at an average price of $31.47, for a total transaction of $619,298.13.

Eton Pharmaceuticals Price Performance

Shares of NASDAQ:ETON opened at $32.40 on Thursday. The firm has a 50 day moving average of $26.59 and a 200-day moving average of $20.03. The stock has a market capitalization of $887.44 million, a PE ratio of -462.79 and a beta of 0.82. The company has a current ratio of 1.21, a quick ratio of 0.88 and a debt-to-equity ratio of 0.62. Eton Pharmaceuticals, Inc. has a 12 month low of $13.09 and a 12 month high of $35.66.

Eton Pharmaceuticals (NASDAQ:ETON) last issued its earnings results on Thursday, May 14th. The company reported $0.05 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.05). The firm had revenue of $24.27 million during the quarter, compared to analyst estimates of $22.31 million. Eton Pharmaceuticals had a negative net margin of 1.70% and a negative return on equity of 5.68%. On average, equities research analysts predict that Eton Pharmaceuticals, Inc. will post 0.82 EPS for the current fiscal year.

Hedge Funds Weigh In On Eton Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in ETON. Soleus Capital Management L.P. acquired a new position in Eton Pharmaceuticals in the 2nd quarter valued at approximately $4,061,000. Millennium Management LLC increased its position in Eton Pharmaceuticals by 156.3% in the 1st quarter. Millennium Management LLC now owns 355,929 shares of the company’s stock valued at $4,620,000 after acquiring an additional 217,042 shares during the period. Oberweis Asset Management Inc. acquired a new position in Eton Pharmaceuticals in the 3rd quarter valued at approximately $4,180,000. Lumbard & Kellner LLC acquired a new position in Eton Pharmaceuticals in the 3rd quarter valued at approximately $3,831,000. Finally, BNP Paribas Financial Markets increased its position in Eton Pharmaceuticals by 162.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 229,790 shares of the company’s stock valued at $4,993,000 after acquiring an additional 142,094 shares during the period. 27.86% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

ETON has been the subject of several analyst reports. Wall Street Zen upgraded shares of Eton Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, March 21st. Zacks Research cut shares of Eton Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, April 17th. Craig Hallum upped their price objective on shares of Eton Pharmaceuticals from $30.00 to $35.00 and gave the stock a “buy” rating in a research report on Friday, March 20th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Eton Pharmaceuticals in a research report on Tuesday, April 21st. Finally, B. Riley Financial upped their price objective on shares of Eton Pharmaceuticals from $26.00 to $31.00 and gave the stock a “buy” rating in a research report on Friday, March 20th. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Eton Pharmaceuticals presently has an average rating of “Hold” and an average price target of $41.00.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.